Tatyana Kushner

New Capabilities

Flagged that quantitative surface antigen testing will be needed to select patients for Hibsago

The Food and Drug Administration approved Hibsago on October 20 for adults with chronic hepatitis B who have no cirrhosis and have taken antiviral pills for at least six months. In two late-stage trials, 19% of patients who took it had no detectable virus 24 weeks after ending all treatment; none of the 614 placebo recipients did.

Updated Oct 29